Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosnodenvir
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mosnodenvir (JNJ-64281802, also known as JNJ-1802) is a first-in-class small molecule antiviral developed for the prevention and treatment of dengue infection. It acts as a direct inhibitor of dengue virus replication by blocking the interaction between two essential viral proteins, NS3 and NS4B, thereby preventing viral RNA replication. Mosnodenvir demonstrates potent pan-serotype activity against all four dengue serotypes in preclinical models and has shown efficacy in both mouse and non-human primate studies. Clinical trials have demonstrated that it is generally safe and well-tolerated in healthy adults. The drug is being developed by Janssen (Johnson & Johnson) for both prophylactic and therapeutic use against dengue[1][3][4][5][6].
- Other names
- mosnodenvir
02
Targets
NS4A-2K-NS4B (Dengue virus NS4A-2K-NS4B precursor)NS3 (Dengue virus NS3 protein)NS4B (Hepatitis C virus NS4B)
Beyond the preview
Go deeper on mosnodenvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosnodenvir.